Stock TITANBIO6 TITAN BIOTECH LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Titan Biotech Limited

Equities

TITANBIO6

INE150C01011

Pharmaceuticals

Market Closed - Bombay S.E.
Other stock markets
 03:30:54 31/05/2024 pm IST 		5-day change 1st Jan Change
541 INR -0.70% Intraday chart for Titan Biotech Limited -0.69% +32.07%
29/05 Titan Biotech Limited Recommends Dividend for the Financial Year Ended on 31 March, 2024 CI
29/05 Titan Biotech Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024 CI

Valuation

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Capitalization 1 487.2 371.9 352.4 1,533 2,166 1,627
Enterprise Value (EV) 1 737.5 589.6 572.9 1,639 2,215 1,663
P/E ratio 15.7 x 10.6 x 4.99 x 5.05 x 8.55 x 6.55 x
Yield 1.19% - 2.34% 0.81% 0.57% 0.91%
Capitalization / Revenue 0.83 x 0.57 x 0.44 x 1.08 x 1.42 x 1.13 x
EV / Revenue 1.26 x 0.91 x 0.72 x 1.15 x 1.45 x 1.15 x
EV / EBITDA 10.5 x 6.65 x 4.25 x 3.56 x 5.44 x 5.75 x
EV / FCF -11 x -28.2 x -23.1 x 10.5 x -96.7 x 61 x
FCF Yield -9.06% -3.55% -4.32% 9.56% -1.03% 1.64%
Price to Book 1.92 x 1.16 x 0.9 x 2.23 x 2.19 x 1.48 x
Nbr of stocks (in thousands) 7,739 8,264 8,264 8,264 8,264 8,264
Reference price 2 62.95 45.00 42.65 185.6 262.0 196.8
Announcement Date 01/10/18 04/09/19 27/08/20 25/08/21 31/08/22 05/09/23
1INR in Million2INR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Net sales 1 587.2 649.1 794.4 1,422 1,530 1,440
EBITDA 1 70.08 88.65 134.9 460.3 407.3 289.2
EBIT 1 61.95 72.59 117 441.9 386.9 268
Operating Margin 10.55% 11.18% 14.72% 31.07% 25.28% 18.61%
Earnings before Tax (EBT) 1 42.49 55.44 104 427.1 382 319.4
Net income 1 31.08 35.22 70.66 303.4 253.3 248.4
Net margin 5.29% 5.43% 8.89% 21.33% 16.55% 17.25%
EPS 2 4.016 4.260 8.550 36.71 30.66 30.06
Free Cash Flow 1 -66.85 -20.91 -24.77 156.6 -22.9 27.28
FCF margin -11.39% -3.22% -3.12% 11.01% -1.5% 1.89%
FCF Conversion (EBITDA) - - - 34.02% - 9.43%
FCF Conversion (Net income) - - - 51.63% - 10.98%
Dividend per Share 2 0.7500 - 1.000 1.500 1.500 1.800
Announcement Date 01/10/18 04/09/19 27/08/20 25/08/21 31/08/22 05/09/23
1INR in Million2INR
Estimates

Balance Sheet Analysis

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Net Debt 1 250 218 220 105 49.9 36.5
Net Cash position 1 - - - - - -
Leverage (Debt/EBITDA) 3.573 x 2.456 x 1.634 x 0.2288 x 0.1225 x 0.1261 x
Free Cash Flow 1 -66.9 -20.9 -24.8 157 -22.9 27.3
ROE (net income / shareholders' equity) 12.3% 13.2% 20.8% 55.6% 32.1% 25.3%
ROA (Net income/ Total Assets) 6.95% 7.47% 10.4% 31.3% 19.8% 13.8%
Assets 1 446.9 471.8 680.3 970.7 1,279 1,799
Book Value Per Share 2 32.80 38.90 47.40 83.20 119.0 133.0
Cash Flow per Share 2 0.9500 2.270 2.220 6.600 18.90 5.890
Capex 1 57.6 44.5 40.1 30.1 110 129
Capex / Sales 9.8% 6.85% 5.05% 2.12% 7.18% 8.96%
Announcement Date 01/10/18 04/09/19 27/08/20 25/08/21 31/08/22 05/09/23
1INR in Million2INR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
TITAN BIOTECH LIMITED Stock Titan Biotech Limited
+32.07% 53.56M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+40.73% 739B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+32.83% 598B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.30% 353B
MERCK & CO., INC. Stock Merck & Co., Inc.
+15.15% 318B
ABBVIE INC. Stock AbbVie Inc.
+4.05% 285B
ASTRAZENECA PLC Stock AstraZeneca PLC
+15.00% 240B
ROCHE HOLDING AG Stock Roche Holding AG
-5.52% 206B
AMGEN INC. Stock Amgen Inc.
+6.17% 164B
PFIZER, INC. Stock Pfizer, Inc.
-0.45% 162B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. TITANBIO6 Stock
  4. Financials Titan Biotech Limited